Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Mirum Pharmaceuticals Inc (MIRM)

306 + Investors. Track Smart Money conviction in MIRM. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +29
Streak
7Q ▲
Buyers last Q
59%

Smart Money Signals — MIRM

Based on 307 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q
For 7 consecutive quarters, more hedge funds added MIRM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
307 hedge funds hold MIRM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +44% more funds vs a year ago

fund count last 6Q
+94 new funds entered over the past year (+44% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 59% buying

185 buying126 selling
Last quarter: 185 funds bought or added vs 126 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new MIRM position: 34 → 70 → 61 → 67. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

41% of holders stayed for 2+ years

■ 41% conviction (2yr+) ■ 23% medium ■ 35% new
127 out of 307 hedge funds have held MIRM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +28% but shares only +12% — price-driven

Value
+27%
Shares
+11%
Last quarter: the total dollar value of institutional holdings rose +28%, but actual share count only changed +12%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

37 → 34 → 70 → 61 → 67 new funds/Q
New funds entering each quarter: 34 → 70 → 61 → 67. A growing number of institutions are discovering MIRM each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 46% veterans vs 41% newcomers

■ 46% veterans ■ 12% 1-2yr ■ 41% new
Entry-cohort mix of 312 holders: 144 (46%) are 2+ year veterans, 39 entered 1–2 years ago, and 129 (41%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 37% AUM from major funds

37% from top-100 AUM funds
53 of 305 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MIRM

In 2026 Q1, 185 hedge funds were net buyers of MIRM (67 opened a new position, 118 added to an existing one), while 126 reduced or exited (88 trimmed, 38 sold completely) — a 59% buyer ratio, indicating a slight buying edge. This marks 7 consecutive quarters of net institutional buying — a persistent conviction signal. 37% of total institutional value in MIRM is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +29 funds (more new holders than closures). Total institutional holders: 307.

Hedge Fund Ownership: MIRM

How many hedge funds hold MIRM — quarterly history vs. share price
Quarterly hedge fund ownership of MIRM vs. share price

Market Analysis: MIRM

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MIRM

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Mirum Pharmaceuticals Inc (MIRM) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MIRM has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 84d ago
MIRM
+15.9%
XLV
+2.8%

MIRM outperformed XLV by +13.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 39d ago
MIRM
+4.8%
XLV
+3.9%

Since the filing became public, MIRM outperformed XLV by +0.9% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Growing Institutional Interest

Quality funds are building positions — conviction is rising but not yet widespread.

32 top-rated funds 7 high-conviction
Consensus
6.6
/ 10
breadth
×
Elite
6.2
/ 10
conviction
Hedge Fund Positioning: MIRM
306 + Investors

Track Smart Money conviction in MIRM. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 306 278 10.07%
13F Shares 68M 61M 11.76%
Total Value $6.02B $4.71B 27.7%
New Positions 67 61 +6
Increased Positions 117 104 +13
Closed Positions 39 48 -9
Reduced Positions 84 78 +6
Total Calls 4 4 -
Total Puts 3 2 50.0%
PUT/CALL Ratio 0.75 0.5 Neutral

Statistics: MIRM

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

306 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MIRM. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MIRM holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Frazier Life Sciences Management, L.P. 18.25% 7,679,684 $709.4M
2 Boone Capital Management LLC 11.92% 421,236 $38.9M
3 Novo Holdings A/S 9.92% 1,325,000 $122.4M
4 Trails Edge Capital Partners, LP 7.05% 333,312 $30.8M
5 Tang Capital Management LLC 5.80% 1,236,027 $114.2M
6 Bvf Inc/Il 4.66% 1,584,727 $146.4M
7 Palo Alto Investors LP 4.59% 325,175 $30.0M
8 Highlander Partners, L.P. 4.45% 122,980 $11.4M
9 Rock Springs Capital Management LP 4.42% 811,294 $74.9M
10 First Turn Management, LLC 4.13% 400,464 $37.0M
11 Patient Square Capital LP 3.77% 230,000 $21.2M
12 Octagon Capital Advisors LP 3.46% 338,900 $31.3M
13 Atle Fund Management AB 3.03% 195,768 $9.4M
14 TCG Crossover Management, LLC 2.81% 1,062,049 $98.1M
15 Next Century Growth Investors LLC 2.58% 385,539 $35.6M
16 NAN FUNG TRINITY (HK) Ltd 2.36% 232,679 $21.5M
17 Eventide Asset Management, LLC 2.15% 1,408,871 $130.1M
18 Penn Capital Management Company, LLC 1.84% 256,767 $23.8M
19 Essex Investment Management Co LLC 1.58% 108,338 $10.0M
20 Soleus Capital Management, L.P. 1.50% 400,306 $37.0M
21 Paradigm Biocapital Advisors LP 1.18% 625,000 $57.7M
22 Emerald Advisers, LLC 1.16% 397,263 $36.7M
23 Emerald Mutual Fund Advisers Trust 1.12% 250,399 $23.1M
24 Rhenman & Partners Asset Management AB 1.06% 92,605 $8.6M
25 Logos Global Management LP 0.92% 200,000 $18.5M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Mirum Pharmaceuticals Inc (MIRM)

What does the Smart Money Trend signal show for MIRM?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added MIRM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for MIRM?

Slight buying edge — 59% buying: Last quarter: 185 funds bought or added vs 126 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MIRM holders?

Strong quality — 37% AUM from major funds: 53 of 305 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held MIRM?

41% of holders stayed for 2+ years: 127 out of 307 hedge funds have held MIRM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Mirum Pharmaceuticals Inc (MIRM) following the 2026 Q1 hedge fund 13F filings?

As of today, MIRM has moved +4.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +0.9%. Since the quarter end (March 31, 2026), MIRM has gained +15.9% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →